CSL wins $230 million H1N1 vaccine order
Monday, 01 June, 2009
CSL's US subsidiary, CSL Biotherapies, has signed a $230 million (USD180 million) contract with the US Department of Health and Human Services (HHS) to provide Novel A (H1N1) influenza vaccine in bulk form.
CSL has also announced it will supply the Novel A (H1N1) vaccine to Australia.
The vaccine will be manufacturered at CSL's facility in Parkville, Victoria, and will support the HHS pre-pandemic influenza preparation efforts.
The new vccine will be tested in clinical trials funded by HHS.
CSL has declared that it will maintain its committment to supply seasonal influenza vaccines to Australia, the US and other markets.
Scientists uncover how cancer cells hide from immune system
By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...
Vanillin flavouring in vapes may disrupt embryo development
Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
